We have closed an investment, in the first tranche of a financing round of up to £2m, in Sphere Fluidics for the University of Cambridge Enterprise Fund II and the final investment for Parkwalk Fund IV. This follows the UoCEF I investing in February 2013.
Sphere Fluidics is an established, Life Sciences company which has developed unique products for use in single cell analysis and characterisation and provides collaborative R&D services in this area.
The company was founded on IP generated by the University of Cambridge and has in-licensed 10 patent families from the University and other leading institutions. The core technology is now protected by 51 patents and has been developed with £2.3m of equity and over £7m of grants.
